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T

he activity of the p53 gene product is regulated
by a plethora of posttranslational modiﬁcations.
An open question is whether such posttranslational
changes act redundantly or dependently upon one
another. We show that a functional interference between
speciﬁc acetylated and phosphorylated residues of p53
inﬂuences cell fate. Acetylation of lysine 320 (K320)
prevents phosphorylation of crucial serines in the NH2terminal region of p53; only allows activation of genes
containing high-afﬁnity p53 binding sites, such as p21/
WAF; and promotes cell survival after DNA damage.
In contrast, acetylation of K373 leads to hyperphosphoryla-

tion of p53 NH2-terminal residues and enhances the interaction with promoters for which p53 possesses low DNA
binding afﬁnity, such as those contained in proapoptotic
genes, leading to cell death. Further, acetylation of each
of these two lysine clusters differentially regulates the interaction of p53 with coactivators and corepressors and
produces distinct gene-expression proﬁles. By analogy
with the “histone code” hypothesis, we propose that the
multiple biological activities of p53 are orchestrated and
deciphered by different “p53 cassettes,” each containing
combination patterns of posttranslational modiﬁcations
and protein–protein interactions.

Introduction
The product of the p53 gene is capable of inducing transcription
activation or repression of a variety of genes, which in turn trigger
cell cycle arrest and promote apoptosis, differentiation, or senescence (Vousden and Prives, 2005). p53 levels and activity are
regulated by numerous stress-induced posttranslational modifications that converge on two distinct domains of the protein
(Appella and Anderson, 2001). A kinase cascade phosphorylates
several serine residues in the p53 NH2-terminal region. Among
these, phosphorylation of serine 15, 20, and 46 and threonine 18
are of most significance, as they act by promoting p53 stabilization (Unger et al., 1999; Knights et al., 2003), by preventing
nuclear export (Zhang and Xiong, 2001), or by favoring p53 recruitment on specific sets of promoters (Oda et al., 2000). A second pathway targets the p53 COOH terminus and involves the
activity of at least two classes of acetyltransferases, p300/CBP
and p300/CBP-associated factor (PCAF; Avantaggiati et al.,
C.D. Knights and J. Catania contributed equally to this paper.
Correspondence to Maria Laura Avantaggiati: ma364@georgetown.edu
Abbreviations used in this paper: ChIP, chromatin immunoprecipitation; CPI,
cyclopropylpyrroloindole; EMSA, electrophoretic mobility shift assay; PCAF,
p300/CBP-associated factor; WT, wild-type.
The online version of this article contains supplemental material.
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1997; Lill et al., 1997). p300/CBP acetylates lysines located in
the last COOH-terminal portion of p53, specifically, lysines 370,
372, 373, and 382 (Gu and Roeder, 1997). PCAF has been linked
to acetylation of a single residue, lysine 320, located within a
flexible linker domain nearby the oligomerization domain, which
also contains a nuclear localization signal (Sakaguchi et al., 1998;
Liu et al., 1999). These initial studies demonstrated that all these
acetylation events lead to enhancement of p53 DNA binding
activity in vitro. More recently, acetylation has been shown to
stimulate the p53–DNA interaction in vivo as well (Luo et al.,
2004), in agreement with the original proposal that acetylation
relieves the inhibitory role exerted by the COOH terminus on p53
DNA binding capacity (Prives and Manley, 2001; Luo et al.,
2004). However, thus far, the biological significance of individual
acetylation of each of these lysine clusters is unclear.
The proapoptotic activity is the most ancestral function of
p53, but additional and more complex activities have clearly appeared during evolution. This is argued based on the properties
of the p53 protein of Drosophila melanogaster, dp53, which differs from its human counterpart because of its exclusive role in
promoting apoptosis. Similarly, the Caenorhabditis elegans homologue of p53, CEP-1, displays predominantly proapoptotic
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activity (Derry et al., 2001). The evolution of p53 toward cell
cycle regulatory functions in complex multicellular organisms
may reflect the need of cells to deal with various forms of stress
in a more advantageous fashion and to mount adaptive responses
that preserve the life of tissues with limited proliferative potential.
In fact, in mammalian cells, the effects of p53 on cellular growth
are pleiotropic and exhibit cell type specificities, and the p53induced cell cycle arrest, although prolonged, is often reversible
(Bates et al., 1999). This reversibility is presumably important
in conditions of “repairable” cellular damage, for resumption of
proliferation when apoptosis can be avoided. Yet, the molecular
basis for p53’s ability to commit cells toward these different
outcomes is still an object of intense investigation. Given the
large repertoire of p53-responsive genes, one possibility is that
a particular combination of target genes, activated or repressed,
may determine whether cells will survive or die after engagement of p53 activity. Because cells are continuously exposed to
genotoxic signals of different nature and intensity, they must
have elaborated ways that allow p53 to interact with specific
classes of genes but not with others, ultimately leading to adaptation and differential susceptibility to stress.
How, then, does p53 select such combination patterns?
Important determinants of selectivity are likely the accessibility of
chromatin and the structural characteristics of the DNA consensus
sequences within p53-responsive elements, which show a surprisingly high degree of variation (Resnick and Inga, 2003; Tomso
et al., 2005). When several p53-response elements were analyzed
for their ability to be activated in a yeast-based assay that eliminates the influence of chromatin on transcription, an unexpected
1,000-fold difference in p53 transactivation ability was detected
depending on the central sequence present within each response
element. In addition, tumor-derived p53 mutants that have altered
conformation compared with the wild-type (WT) protein exhibit
distinct promoter specificities and retain their ability to transactivate certain promoters but not others. Thus, the intrinsic DNA
binding affinity of p53, together with conformational changes,
may contribute to differential gene activation. Posttranslational
modifications may play an important role in modifying both p53
conformation and p53 affinity for its downstream targets.
In this study, we have characterized the functional and
biochemical properties of p53 mutants mimicking constitutive
acetylation as well as of truly acetylated p53. We show that two
distinct acetylable clusters at position 373 (K373) and 320
(K320) regulate p53 activity in quite a different fashion.
A model is proposed to explain how site-specific acetylation
operates and cross-talks with other events, such as additional
posttranslational modifications and protein–protein interactions,
to modify p53 affinity for different classes of genes during stress
signals, leading to cell survival or death.

Results
Different kinetics of acetylation of K320
and K373 in response to DNA damage

We began our studies by asking how acetylation of different
sites is regulated during stress signals. For these experiments we
used a p53-null, human lung carcinoma cell line, H1299, where
534
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Figure 1. The kinetics of K320 and K373 acetylation of p53 in response
to DNA damage correlate with cell cycle arrest or apoptosis. (A) Cell cycle
proﬁle of H1299 cells expressing tetracycline-inducible p53. Cells were
left untreated or treated with 5 μM adozelesin or bizelesin or with 100 μM
etoposide after a 24-h induction of p53 with tetracycline. Flow cytometry
was performed as described previously (Avantaggiati et al., 1997). The
percentage of cells displaying Sub-G1, G1, S, or G2/M DNA content is
provided as an inset for each histogram. (B) H1299 cells expressing p53
were treated as indicated at the top of each panel in A. At different times
after treatment, cells were harvested and cell lysates were immunoprecipitated with a polyclonal antibody recognizing acetyl-p53K320 (Acp53K320)
or acetyl-p53K373 (Acp53K373) or with an antibody recognizing total p53,
as indicated on the left side of each panel. The products of these reactions
were then subjected to immunoblot with a mixture of monoclonal antibodies directed against the p53 NH2 terminus (DO-1) and COOH terminus
(PAb421). Black lines indicate that intervening lanes have been spliced out.
(C) H1299 cells expressing WT p53 were left untreated or treated with
increasing concentrations of adozelesin or bizelesin (1, 50, or 500 μM),
harvested after 6 h, and analyzed as in B.

the expression of p53 was reconstituted via a tetracyclineinducible vector. The kinetics of acetylation of K320 and K373
were then studied in cells exposed to the radiomimetic DNAalkylating agents adozelesin and bizelesin or to the topoisomerase inhibitor etoposide. Adozelesin and bizelesin are members
of the cyclopropylpyrroloindole (CPI) family of DNA minor
groove alkylating agents endowed with anti-tumor activity (Lee
et al., 1994). Adozelesin is a monofunctional CPI, whereas bizelesin is a CPI dimer that can alkylate adenines on one or both
DNA strands, forming double-stranded DNA cross-links that
render it more cytotoxic than adozelesin. Thus, these drugs allowed us to assess whether different types of DNA damage trigger
distinct acetylation events. In cells treated with adozelesin, which
arrested predominantly in G1 and did not undergo apoptosis
(Fig. 1 A), acetylation of K373 was no longer visible after 4–12 h
of treatment, whereas acetylation of K320 remained detectable for
24 h after the addition of the drug (Fig. 1 B). In contrast, treatment
with bizelesin or etoposide resulted in robust and sustained levels
of acetylation of K373 and induced an initial arrest in G2/M
followed by apoptosis (Fig. 1 A and not depicted).
These results provided evidence that the kinetics of K320
and K373 acetylation can be dissected depending on the type

Figure 2. Different effects of p53 acetylation
mutants on cell growth. (A) Cell cycle proﬁle of
H1299 cells expressing p53 proteins (indicated at the top of panels). Cells were left
untreated or treated with 50 μM adozelesin,
50 μM bizelesin, or 100 μM etoposide. Drugs
were added 24 h after tetracycline addition,
and cells were grown for an additional 24–48 h
and then harvested and stained with propidium iodide (shown in all panels) and with BrdU
(not depicted), and their cell cycle proﬁle was
determined. (B and C) Tetracycline-induced
H1299 cells were left untreated or treated with
1 μM adozelesin for 4 h. Cells were extensively washed and incubated in drug-free media but in the presence of tetracycline for an
additional 24 h. Tetracycline was then removed to shut off p53 expression, and cells
were allowed to recover for 6–8 d, after which
one dish was stained with Coomassie brilliant
blue (B) and the remaining were used for cell
counting (C). Error bars indicate SEM.

of damage. To test whether the amount of DNA damage also
influences the extent and sites of acetylation, we treated cells
expressing p53 with increasing doses of adozelesin or bizelesin
(Fig. 1 C). In this case, we observed a dose-dependent enrichment of the levels of K373 acetylation, whereas acetylation of
K320 was only modestly enhanced. Thus, various acetylation
sites act as a “sensor” system for the type and extent of DNA
damage and may differentially regulate the ability of p53 to
induce cell cycle arrest or apoptosis.
Opposing effects of K320 and K373
acetylation on the ability of p53
to induce apoptosis

To gain more insights into the function of acetylation, we created
gain-of-function p53 acetylation mutants. Glutamine in place of
lysine has been shown to mimic the effects of a constitutive acety-

lation in the case of histones and of p53 (Luo et al., 2004), probably because glutamine is a neutral amino acid, which, like
N-acetyl-lysine, has an amide group that can function as a hydrogen bond donor or acceptor. Thus, we constructed mutants harboring lysine to glutamine substitutions at position 320 (Q320),
a triple mutant at position 370/372/373 (Q373), or at all these
positions (DM). Native p53 and its derivative acetylation mutants were expressed in the p53-null cell line, H1299, via a tetracycline-regulated promoter (see Fig. 4 F and Fig. S1 C, available
at http://www.jcb.org/cgi/content/full/jcb.200512059/DC1, for
typical expression levels of these p53 proteins). Cells were
treated with different DNA-damaging agents, and their cell cycle
distribution was assessed (Fig. 2 A). In untreated cells, expression of native p53 produced an arrest, especially at the G1 phase,
accompanied by a reduction of cells transiting throughout
S phase, as expected. The cell cycle profiles of cells harboring
P53
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p53 acetylation mutants were different in several ways: a higher
percentage of cells expressing p53DM arrested in G1, whereas
cells harboring p53Q373 arrested markedly in G2/M, suggesting
that these residues predominantly influence the activity of p53
on the G2 checkpoint. To rule out the possibility that these differences may be due to unique clonal characteristics of these p53
cell lines, similar experiments were performed by using either
additional individual clones or polyclonal mixtures. The analysis
of the growth characteristics and viability of these cells produced
substantially similar results (Fig. S1, A and B).
To understand how site-specific acetylation of p53 affects
sensitivity to anti-tumor agents, cells were treated with the DNAdamaging agents adozelesin, bizelesin, or etoposide. In drugtreated cells, expression of p53Q320 activated the G1 checkpoint
and conferred significant protection from cell death compared
with native p53-expressing cells, which underwent apoptosis
when treated with bizelesin or etoposide. Quite in contrast,
p53Q373 had a strong chemosensitizing effect, as the majority of
cells bearing this mutant underwent apoptosis early after drug
treatment. In cells harboring the mutant at all positions, the percentage of apoptosis was significantly lower than that observed
in both native- and p53Q373-expressing cells, suggesting that the
mutation of K320 has a dominant effect in preventing cell death.

isolated from native or p53 acetylation mutant–expressing cells
were subjected to immunoblot analysis with antibodies recognizing p300, PCAF, HDAC1, mSin3, and p53 itself. HDAC1 and
mSin3 are components of a corepressor complex, which plays
an important role in the ability of p53 to silence transcription of
critical antiapoptotic promoters (Murphy et al., 1999). As shown
in Fig. 3 A, the p53Q373 mutant coprecipitated a significantly
higher amount of p300 compared with native p53 and p53Q320
and, conversely, p53Q320 was more efficient in interacting with

K320 acetylation favors resumption
of proliferation and cell survival

Results presented thus far are consistent with the possibility that
acetylation of residues around position 373 activates the apoptotic pathway, whereas acetylation of K320 suppresses cell death.
We then hypothesized that acetylation of K320 could function
to disable or delay the apoptotic program elicited by p53, thus
allowing cells to resume proliferation in conditions of moderate
DNA damage once p53 signaling is extinguished. To test this,
cells expressing native p53 or p53 acetylation mutants were
pulsed with low concentrations of adozelesin for a short period
of time in the presence of tetracycline. p53 expression was shut
off by removing tetracycline from the media 24 h after drug
treatment, and cell growth was monitored for several days thereafter (Fig. 2, B and C). In these conditions, untreated and drugtreated cells expressing p53Q373 displayed a significant loss of
viability, whereas cells expressing p53Q320 were able to resume
proliferation. In addition, cells expressing p53DM again displayed a phenotype intermediate between that exhibited by
p53Q320 and -Q373. These results argue against a simple model
in which the number of acetylated lysines controls p53-apoptotic
activity in a dose-dependent manner. Rather, they suggest that
the effects of acetylation are strictly position specific and place
acetylation of K320 as a central event in favor of cell survival.
Site-speciﬁc acetylation differentially
inﬂuences the interaction of p53
with transcriptional coactivators
and corepressors

Posttranslational modifications regulate p53’s interaction with
other cellular proteins. We next asked whether acetylation influences the association with factors known to bind p53, particularly to coactivators and corepressors. p53 protein complexes
536
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Figure 3. Interaction of cofactors with acetylated forms of p53 protein.
(A) Nuclear extracts prepared from H1299 cells treated with tetracycline
were immunoprecipitated with an anti-Flag antibody, eluted with Flag
peptide, and run on 4–20% gradient gels. The presence of p300, PCAF,
HDAC1, and mSin3 was revealed by immunoblotting with speciﬁc antibodies. (bottom) Total p53 levels contained in the anti-Flag–speciﬁc immunoprecipitation. (B) H1299 cells expressing native p53 were treated with
etoposide for the indicated times. Cell extracts were immunoprecipitated
with the anti-Acp53K373–speciﬁc antibody. The presence of p53, SIRT1/
Sir2, or HDAC1 in these reactions was revealed via immunoblots with speciﬁc antibodies, as indicated at the side of each panel. The bottom panel
represents 20% of the total amount of precipitated p53 protein. (C) Analysis of the interaction between truly acetylated forms of p53 and p300.
A549 cells expressing WT p53 were treated for 16 h with 50 μM adozelesin and immunoprecipitated with either Acp53K320 (lane 1) or Acp53K373
(lane 2). These reactions were subjected to p53- and p300-speciﬁc immunoblots. The total levels of p300 were determined with the C-20 (Santa
Cruz Biotechnology, Inc.) antibody after immunoprecipitation, whereas
p53 levels were detected from total extract (lane 3).

PCAF, indicating that each acetylation cluster specifically modifies the interaction of p53 with distinct types of histone acetyltransferases. Further, p53Q373 coprecipitated higher amounts of
HDAC1 than native p53 or p53Q320 (Fig. 3 A). To further substantiate these findings, we studied the binding pattern of endogenously, “truly” acetylated p53 after treatment with etoposide.
Consistent with data obtained with the acetylation mimics,
acetylated p53 detected with the anti–acetyl-K373–specific antibody coprecipitated a significant amount of HDAC1 and SIRT1
(Fig. 3 B). Interestingly, these deacetylase–p53 complexes were
detectable for at least 12 h after treatment, indicating that
acetylation of K373 can stabilize the interaction of p53 with
deacetylase–corepressor complexes. Similarly, in A549 cells
treated with adozelesin, truly acetylated p53 at K373 displayed
a significantly stronger affinity for p300 compared with acetylK320 p53 (Fig. 3 C, compare lanes 1 and 2). These data further
support the notion that glutamine in place of lysine mimics the
effects of constitutive acetylation and imply that acetylation of
different sites selectively modifies the affinity of p53 for different types of chromatin-remodeling enzymes.
Delineation of the genetic program elicited
by differently acetylated forms of p53

p53 conveys complex cellular responses that are due in part to
its ability to function as a transactivator and as a transrepressor.

To understand how acetylation operates, we performed microarray analysis on cells expressing native p53, p53Q320, and
p53Q373 (Table S1, available at http://www.jcb.org/cgi/content/
full/jcb.200512059/DC1). Approximately 40,000 probe sets
were examined by using high-density oligonucleotides arrays at
12 h after addition of tetracycline to the media. For this analysis,
we applied a present call noise filter (one in six arrays), foldchange thresholds (>2), and a p-value of <0.05 as our initial
dataset for preliminary analysis and gene identification, leading
to further consideration of 27,000 transcripts. To more specifically identify genes regulated in an acetylation-dependent
manner, genes found in the array platform derived from cells
expressing native p53 served as background, so that p53Q373 or
-Q320 gene-expression patterns were directly compared with
native p53. With this analysis, we determined that both p53Q320
and -Q373 lead to an increase of a similar number of transcripts,
whereas p53Q320 repressed 955 genes, which was significantly
less than the 1,576 transcripts repressed by p53Q373. Thus,
p53Q373 is a stronger repressor than p53Q320, consistent with
its ability to interact more efficiently with HDAC1 and SIRT1/
mSir2 (Fig. 3). Further, in agreement with the observation that
p53Q373 sensitizes cells to apoptosis, many of the genes found
activated by this mutant promote cell death (i.e., APAF1,
caspase 6, pig3, pig11, AMID, PCBP4, and IGFBP3), and
a significant number of those repressed promote survival

Figure 4. Characterization of the geneexpression pattern elicited by p53 acetylation
mutants. (A) Clustering of genes regulated by
p53 acetylation mimics. Probes corresponding
to fold change >2 were hierarchically clustered. Data from each probe are in the columns, and each experiment is shown as
a row. Red and green denote increased and
decreased expression levels, respectively,
with the intensity reﬂecting the magnitude of
change. (B) Validation of microarray data by
semiquantitative RT-PCR. To verify oligonucleotide microarray results, semiquantitative
RT-PCR was used to estimate the amount of
RNA from three altered genes in WT p53–,
p53Q320-, and p53Q373-expressing cells (+).
To ensure that clonal variability does not
contribute to the different levels of gene expression, mRNA was collected from H1299-WT,
-Q320, and -Q373 cells in the absence of
tetracycline (−). Densitometry was performed
using Fluor Chem 3.04A software (Alpha Innotech Corp.) and normalized to the β-actin
signal. Fold changes represent the difference for
each mRNA observed within each individual
cell line. Each band detected in the absence
of tetracycline was attributed an arbitrary value
of 1 and compared with the band detected in the presence of tetracycline (lanes 1, 3, and 5 were compared with lanes 2, 4, and 6, respectively).
(C) In vivo interaction of p53 with its DNA binding sites derived from different promoters. Untreated H1299 or H1299 treated with tetracycline were crosslinked with formaldehyde and immunoprecipitated with a polyclonal antibody recognizing p53 (FL393). The amount of p53 proteins contained in these
immunoprecipitation reactions was normalized (E), such that similar amounts of DNA-bound p53 were used for sequence-speciﬁc ampliﬁcation of the
promoters of p21/WAF, PIG3, BAX, and p53AIP1. (D) H1299 cells were treated with tetracycline to induce WT p53 protein and then subjected to ChIP.
Acetylated p53 was precipitated by using antibodies directed against Acp53K320 or Acp53K373/K382, whereas total p53 was precipitated with the polyclonal
p53 antibody. Promoter binding was assessed as described in C. Input represents 2% of the total DNA content used for precipitation. (E) Equalization of
p53 proteins used for the ChIP assays in C. p53 levels in each cell line were predetermined after DNA–protein cross-linking by direct immunoblot and
before the immunoprecipitation reaction (not depicted). The amounts of cell extract were then adjusted based on this preliminary assessment, so that equivalent amounts of each acetylation mutant were subjected to immunoprecipitation and subsequent PCR ampliﬁcation. The two panels show typical levels of
p53 proteins after this equalization, derived from two different experiments. (F) H1299 cells were left untreated (time 0) or were treated with tetracycline
for 12 and 24 h. The type of p53-expressing cell line is indicated at the top of the panels. Cell lysates were prepared and subjected to immunoblots with
antibodies recognizing p53, p21/WAF, Bax, and actin.

P53
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(i.e., survivin, API5, BIRC3, and IL31RA). The behavior of
p53Q320 was, instead, opposite. For example, several of the
proapoptotic genes activated by p53Q373 were repressed by
p53Q320 (i.e., APAF1 and pig11) relatively to native p53 and,
vice versa, some antiapoptotic genes repressed by p53Q373
were activated by p53Q320 (i.e., survivin, TRAF2, AATF, and
BIRC4). Numerous other genes were also conversely expressed
between p53Q320 and -Q373 (e.g., cyclin B1; Table S1, bold).
To gain a further unbiased analysis of this phenomenon, a “heat
map” was generated, which demonstrated differential, if not
contrasting, gene-expression patterns between p53Q320 and
-Q373 (Fig. 4 A). To validate the gene changes identified with the
microarray platform, semiquantitative PCR was also performed
on various relevant apoptotic- and growth arrest–related genes,
some of which are shown in Fig. 4 B. This approach confirmed
that the regulation of previously known p53 targets, such as pig11
and APAF1, or of new p53-regulated genes like Jagged2, was
significantly different depending on the site of the mutation.
Although we cannot completely exclude the possibility
that at least some of these changes are an epiphenomenon, reflecting events secondary to p53 activation, many of the relevant
genes differentially modulated by p53Q320 and -Q373 are wellknown primary targets of p53, for example, APAF1, pig11,

survivin, caspase 6, mdm2, and cyclin B1. In addition, a large
number of newly identified genes that we found up-regulated in
the microarray platform contain p53 binding elements (Table I),
thus suggesting that they might be direct p53 targets. In addition,
this approach indicated that p53Q373, unlike p53Q320, predominantly controls the expression of genes that regulate apoptosis.
Acetylation of various sites differentially
inﬂuences the interaction of p53
with downstream promoters

Data based on the microarray analysis suggested that acetylation
of K320 or K373 may lead to direct p53 binding onto different
types of promoters. However, previous studies showed that simultaneous acetylation of multiple COOH-terminal lysines enhances the DNA binding activity of p53 on typical DNA binding
elements (Gu and Roeder, 1997; Luo et al., 2004). In light of our
results, we decided to investigate how each of the acetylation
clusters individually influences p53–promoter interactions. The
DNA binding properties of acetylation mutants and of truly acetylated p53 were studied in vivo in chromatin immunoprecipitation
(ChIP) assays. To assess the influence of chromatin on the ability of p53 to interact with its DNA consensus sites, we also performed electrophoretic mobility shift assays (EMSAs) with

Table I. Putative p53 binding sites in the genes up-regulated by p53 acetylation mimics

Q320
axl
cdk2
rad9
atm
mad2l1
mcm5
mcm6
birc5-survivin
cdc6
tnfrsf6b-dcr3
cdc25a
cdc2
skp2
jun
cdkn2c
Q373
csnk1g1
pig11
pml
igfbp3
jagged2
jag1
pig3
ak1
apaf1
casp6
gas6

Gene length

Site location

Score

Putative p53 binding site

62851
25017
27671
162402
27376
44646
55966
30454
34178
64663
51427
35523
51917
23255
25945

47804
9808
22729
89128
25528
23519
41522
15287
26674
13579
13156
1135
41500
3530
6870

100
100
93.66
93.56
93.02
93.01
90.9
90.13
90.89
88.94
93
90.93
95.85
88.92
87.82

GGGCTTGTCC
AAACTTGTCT
ACACAAGTCC
AAGCATGTTT
AATCTAGCTC
AGGCAAGCTC
AGGCATGCTT
AAGCATGCTG
AGACTTGCCT
AAGCTTGTCT
AGTCAAGTCT
TAACAAGCTC
AAACTAGTTT
TGGCTTGGCT
AGGCATGGTG

ACATGGGCT GGGCATGTCT
AGCCCCCAAGAACC AAACTTGCCT
AGATATAGACAG AAACTTGCCC
AAGA ACACTTGTTC
CTTATTTTC AAACATGTTT
TGTCCTCATTGCT AGGCAAGACC
TAATACAAGTGATA TGACTTGTTA
TGAGA GAGCTTGTCA
G TGGCTAGCTA
CAGGG CAGCTTGTGT
CACTATGTTGCCCC AGGCTTGTTT
CTTTCATCAGTCCC AAGCAAGCCA
AAATTGA TGACTTGTTC
GGGCTGGGCCATG AGACTAGTTT
. GAGCATGCCT

148281
40531
68790
29032
47019
56265
27431
28274
110193
34733
32013

12563
13335
1318
25147
18872
29477
8069
1838
79794
18886
11571

100
93.59
93
92.04
89.85
82.78
83.82
83.45
88.99
88.89
82.21

GGACTTGCCT
GCACAAGCCT
AGACTTGCTT
TGACTAGCTT
GAGCATGTTG
ATACATGCTT
AGACATGTTT
TGGCCAGCTC
GGGCAAGCCC
TGGCTTGTTC
CGTCTTGCCC

GTAGTCAGAA GAACTTGTCT
TTTAAGTCAT GAGCTAGTCC
TA AGGCAAGATC
CTTTCACT TAGCATGTTT
GGGTGTGTGGATG GAGCATGTTG
GCTTA TTGCAAGCCT
TTTGCCC TAACAAGTGA
CAAACTTAC AGACTTGTCT
AGACA CCACTTGTTT
AAAGG AGACAAGTGT
TTCAGAAACATTGTAGACTTGTAT

Genes that were activated by p53Q320 or -Q373 in the microarray platform were researched in a p53 database generated at The Rockefeller University (http://linkage.
rockefeller.edu/p53). This database catalogues putative p53 DNA binding elements in 2,583 human genes and 1,713 mouse homologues on the basis of a newly
developed p53MH algorithm. Genes containing putative p53 consensus sites and relative scores are shown. Gene length represents the combined base-pair length
of the promoter and gene sequence. Site location represents the position within the gene length where the listed binding sequence begins. The consensus p53 binding
sequence is PuPuPuC(A_T)(T_A)GPyPyPy.
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in vitro–purified p53 (Fig. S2, available at http://www.jcb.org/
cgi/content/full/jcb.200512059/DC1). A first observation arising
from these experiments was that native p53 bound to the endogenous promoter of p21/WAF with significantly higher affinity
compared with the PIG3, BAX, or p53AIP1 promoters (Fig. 4 C).
Results obtained with EMSAs essentially recapitulated those
seen with the ChIP assays and indicated that p53 possesses
substantially different intrinsic affinity for its DNA binding
elements. Noticeably, both p53Q320 (Fig. 4 C) and its truly
acetylated counterpart immunoprecipitated with the anti–acetyl320 antibody (Fig. 4 D), bound to the high-affinity p21/WAF
promoter more efficiently than native p53 or p53Q373. Conversely, p53Q373, as well as endogenously acetylated p53 at position K373, interacted better with the low-affinity proapoptotic
promoters of BAX (Fig. 4, C and D), PIG3, and p53AIP1 (Fig.
4 C), compared with other p53 proteins. It is important to note
that both the EMSAs and ChIP assays were performed in conditions in which p53 levels were equalized (Fig. 4 E). Thus, these
differences reflect acetylation-mediated changes in the intrinsic
p53’s DNA binding affinity. Furthermore, the different promoter
binding pattern of p53 acetylation mutants resulted in coherent
changes in the expression levels of corresponding encoded products, as demonstrated by the different protein levels of Bax and
p21/WAF in these cell lines (Fig. 4 F). Based on these data, we
infer that acetylation of K373 enhances the interaction of p53,
particularly with low-affinity proapoptotic promoters.
Acetylation inﬂuences p53
nuclear retention and is coupled
to site-speciﬁc phosphorylation

nuclear localization signal (Liang and Clarke, 2001), we suspected that acetylation of this residue might affect the subcellular
localization of p53. In fact, as shown in Fig. 5, the p53 acetylation mimic at position K320 was localized predominantly in the
cytoplasm, whereas p53Q373 was almost exclusively nuclear
(Fig. 5 A). The presence of the mutation at position 320 also
partially placed p53Q373 off the nucleus, as argued by the cytoplasmic localization of p53DM. In addition, when lysines were
replaced with arginine rather than with glutamine, both R320 and
R373 mutants localized in the nucleus (Fig. 5 B), indicating that
neutralization of the positive charge of lysine interferes with nuclear accumulation of p53. Surprisingly, however, the increased
cytoplasmic concentration of p53Q320 and -DM is not sustained
by an increase in nuclear import but rather by an accelerated nuclear export. This is argued because treatment with leptomycin B,
which blocks the activity of the exportin protein Crm1 (Fukuda
et al., 1997), resulted in net nuclear accumulation of both mutants
(Fig. 5 C). To further validate these results, two additional sets
of experiments were performed. First, we studied the subcellular
distribution of truly acetylated p53 in H1299 cells treated with
adozelesin, which enhances the levels of K320 acetylation (Fig.
6 A). Treatment with adozelesin increased the cytoplasmic fraction of p53, and such fraction reacted with the anti–acetyl-320
antibody. Second, we determined the localization of p53 after
overexpression of PCAF or of p300, which acetylate K320 and
K370/372/373, respectively. Overexpression of PCAF resulted in
increased cytoplasmic levels of p53 (Fig. 6 B), in contrast to overexpression of p300, where p53 remained substantially nuclear.

The aforementioned results offer a plausible molecular basis for
the proapoptotic activity exhibited by p53Q373; however, they
do not completely explain the biological effects of the mutant at
position 320. Because K320 is located in a previously identified

Figure 5. Acetyl-mimic Q320 alters the nuclear-cytoplasmic shuttling of p53.
(A and B) Tetracycline-induced H1299 cells were grown on glass coverslips, and 24 h later cells in A and B were stained with an anti-p53 polyclonal antibody (red) and with DAPI (blue). (C) Tetracycline-induced cells
expressing p53Q320 and p53DM were grown in the presence of leptomycin B and subjected to indirect immunoﬂuorescence.

Figure 6. Acetylation of K320 increases the cytoplasmic localization of p53.
(A) Tetracycline-induced WT p53–expressing H1299 cells were left untreated or were treated for 16 h with 50 μM adozelesin and then stained
with a polyclonal antibody recognizing 320-acetylated p53 (Ac-320; red),
a monoclonal antibody recognizing total p53 (green) and DAPI. (B) WT
p53–H1299 cells were transfected with a PCAF or a p300 expression vector for 24 h and then stained with DAPI and with antibodies recognizing
p300, p53, or PCAF, as indicated at the top of each panel.
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The observation that K320 acetylation might place p53
off the nucleus by accelerating nuclear export led us to investigate the possible cross-talk between acetylation and phosphorylation of serine 15 (S15), which has been implicated in nuclear
accumulation (Zhang and Xiong, 2001). As shown in Fig. 7 A,
S15 phosphorylation was almost undetectable in cells expressing p53Q320, whereas the p53Q373 mutant was hyperphosphorylated at this residue compared with other p53 proteins,
suggesting that acetylation and phosphorylation might be functionally linked. To assess whether other specific combination
patterns of acetylation and phosphorylation do exist, we examined the phosphorylation state of S392 and S46. S392 phosphorylation increases the stability and the nuclear localization
of p53 (Kim et al., 2004), whereas phosphorylation of S46 is
specifically involved in mediating the interaction of p53 with
the promoter of the proapoptotic gene p53AIP1 (Oda et al.,
2000). We found that p53Q373, but not p53Q320, was hyperphosphorylated at both sites.
Thus, K320 acetylation negatively interferes with the phosphorylation and the activity of the nuclear export domain of p53,
whereas K373 acetylation enhances the phosphorylation of sites
involved in regulation of retention and accumulation of p53 in the
nucleus, as well as in p53 binding to proapoptotic promoters.
Modiﬁcations of K320 and K373 induce
conformational changes in the NH2
terminus and DNA binding domain of p53

As a whole, our results imply that individual acetylation of lysines 320 and 373 of p53 has general, yet differential, effects on
the intrinsic DNA binding activity and on the ability to interact
with cellular proteins and influences other key posttranslational
modifications, such as phosphorylation. We were interested in
understanding, at a mechanistic level, how these acetylation
events may affect so many important p53 functions. We hypothesized that modifications of K320 or K373 induce conformational changes that in turn influence multiple protein–protein
interactions. To test this, we assayed the ability of p53Q320 and
-Q373 to interact with antibodies recognizing epitopes located
within spatially distant portions of p53 (Fig. 7, B and C).
We used the p53 antibody DO-1, which binds to amino acids
20–25 in the NH2 terminus (B-1); the PAb421 antibody, which
recognizes a COOH-terminal epitope located between amino
acids 372–381 (B-2); and the PAb240 antibody, a typical conformational antibody that recognizes residues 213–217 within
the DNA binding domain (B-3). This latter epitope becomes exposed when p53 is in an inactive mutant conformation or when
WT p53 is bound to DNA (McLure and Lee, 1996). To assess
the accessibility of these epitopes in the absence of other
changes, native or acetylation mutant forms of p53 were purified in vitro to near homogeneity from insect cells infected with
recombinant baculoviruses, and each protein was immunoprecipitated with limiting or saturating amounts of antibodies.
The purity of these preparations is shown in Fig. S3 (available
at http://www.jcb.org/cgi/content/full/jcb.200512059/DC1).
The results of these experiments were striking. Indeed, all three
epitopes were more accessible by their specific antibody in the
case of p53Q320. The increased accessibility of the PAb240
540
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Figure 7. Phosphorylation proﬁle of p53 acetylation mutant proteins.
(A) Cell extracts derived from tetracycline-induced H1299 cells expressing
p53, p53Q320, or p53Q373 were subjected immunoblot with antibodies
recognizing total or S15-phosphorylated p53. p53 levels were equalized
among the different cell lines (bottom), so that similar amounts of each p53
acetylation mutant was probed with anti-phosphorylation–speciﬁc antibodies. S46 or S392 phosphorylation was detected via immunoprecipitation with a p53 polyclonal antibody, followed by immunoblot with anti-p53
antibodies directed against phospho-S46 or -S392. Fold induction for
each phosphorylation site was determined by densitometry by using Fluor
Chem 3.04A software, whereby cells expressing native p53 were attributed an arbitrary value of 1 and signals were normalized for total p53
levels. (B) WT p53, p53Q320, and p53Q373 were puriﬁed from baculovirus-infected cells and immunoprecipitated (IP) with different antibodies,
each recognizing a different epitope, at the concentrations indicated at the
top of each panel. The products of these immunoprecipitations were subjected to immunoblot (IB). The combination of antibodies used is indicated
at the left side of each panel. (C) p53 mutants puriﬁed from baculovirusinfected cells were visualized via Coomassie blue staining (1) or by direct
immunoblot with the DO-1 antibody (2).

epitope can particularly explain the lesser binding of this mutant to low-affinity promoters, as exposure of these residues indicates a partially denatured conformation. In contrast, p53Q373
completely disrupts reactivity with the PAb421, probably because the PAb421 epitope spans within this region. Importantly,
no significant differences were observed when p53 proteins
were immunoprecipitated with a goat polyclonal antibody
(N-19; B-4) or were subjected to direct immunoblot after p53
had been denatured in SDS-PAGE (C-2).
Thus, in vitro, mutations of K320 and K373 impart conformational changes that modify the accessibility of epitopes
located within the NH2 terminus, the central portion, or the
COOH terminus of p53. Likewise, in vivo, acetylation-mediated
changes in the availability of these sites might explain differential interactions with cellular factors, including coactivators and
corepressors, or kinases and phosphatases that in turn influence
transcription and phosphorylation, respectively.

Discussion
Why so many acetylation sites?

Our results are consistent with a model whereby acetylation of
lysines 320 and 373 acts as a finely tuned sensor-effector system that enables p53 to coordinate gene-expression patterns in
response to DNA damage (Fig. 8). We have demonstrated that
various p53 acetylation mutants, as well as truly acetylated p53
(Fig. 4), possess different intrinsic affinities for their downstream

promoters and that acetylation of residues around position K373
is necessary, particularly for binding to low-affinity proapoptotic promoters, such as BAX, both in vitro and in vivo (Fig. 4
and Fig. S2). It is important to note that although the expression
levels of p53Q373 were consistently twofold higher than those
of other p53 proteins (Fig. 4 and Fig. S1) in conditions in which
p53 levels were predetermined and equalized, such as in
EMSAs (Fig. S2), in ChIP assays (Fig. 4), and in the phosphorylation studies (Fig. 7), p53Q373 interacted more strongly with
proapoptotic promoters and was hyperphosphorylated compared with WT p53 or p53Q320. Thus, these changes reflect
qualitative differences in the behavior of this mutant. In light of
these data, p53Q373-mediated activation of proapoptotic promoters might depend on a combination of effects, specifically,
a direct enhancement of the intrinsic DNA binding affinity, hyperphosphorylation of strategic residues, and an increase in p53
nuclear retention that allows occupancy of “hard-to-reach” and
low-affinity promoters. In contrast, we found that p53Q320 interacted efficiently with the high-affinity p21/WAF promoter
but to a lesser extent with the promoters of BAX, p53AIP1, and
PIG3. This correlated with a PAb240+ conformation, indicative of a partially denatured configuration, as well as with decreased phosphorylation of residues that favor nuclear retention
of p53. We interpret these data to conclude that the effects of
K320 acetylation rely, at least in part, on its accelerated nuclear
export (Figs. 5 and 6) and different conformation (Fig. 7), both
of which could prevent p53 from reaching nuclear concentrations and a configuration necessary to efficiently saturate lowaffinity promoters. We have further shown that K373 acetylation
stabilizes the interaction of p53 with p300, HDAC1, and SIRT1/
Sir2 (Fig. 3). These molecular features were linked to an increase in the total number of repressed genes by p53Q373 compared with p53Q320 and with qualitative differences in the
pattern of activated genes (Table S1). Expression of p53Q320,
which interacts with PCAF but has significantly less affinity for
p300 (Fig. 3), appeared instead to correlate with a lower threshold of activation and with a distinct pattern of gene expression.
In addition, an unbiased “heat map” of genes regulated by the
two acetylation mutants clearly demonstrated differential, if not
contrasting, gene-expression patterns between p53Q320 and
-Q373 (Fig. 4 A). Collectively, our results imply that each of the
various clusters of acetylation regulates p53 distribution in different cell compartments and chromatin domains and acts as an
interaction platform for various types of chromatin-remodeling
enzymes to activate specific sets of genes.
The aforementioned differences in the biochemical properties of p53 acetylation mutants are physiologically relevant.
Indeed, cells expressing p53Q320 were capable of promoting
cell survival and resumption of proliferation in conditions of
moderate DNA damage, unlike those harboring p53Q373,
which were irreversibly committed toward apoptosis (Fig. 2).
Thus, in view of the DNA binding properties of the corresponding mutants, it seems legitimate to speculate that acetylation of
K320 enables cells to tune the expression of various p53 target
genes in a way that enhances the ability of cells to survive if the
damage does not accumulate to catastrophic levels. While this
work was in progress, a report showed that p53 activates a cell

Figure 8. p53 cassettes, created by combinations of posttranslational
modiﬁcations and protein–protein interactions, control cell fate. By analogy
with the “histone code” hypothesis elaborated by Strahl and Allis (2000)
and based on data shown in this study, we propose that speciﬁc combinations of posttranslational modiﬁcations generate distinct p53 cassettes that
direct p53 toward precise cellular functions. These p53 cassettes, in addition to directly inﬂuencing key biochemical properties of p53, such as its
DNA binding afﬁnity, also interact speciﬁcally with effector proteins that
participate in deciphering and eliciting a particular response. We envision
that these combination cassettes may exist for many p53 posttranslational
modiﬁcations and establish a modular link between multiple upstream regulators of p53 and downstream events.

cycle checkpoint that responds to glucose availability and promotes survival (Jones et al., 2005). In keeping with our findings,
these observations lead to the important conclusion that the cell
cycle and death pathway are under the control of a subpopulations of p53 with very distinct biochemical properties.
As noted previously, the p53 protein of D. melanogaster
(dp53) differs from its human counterpart because of its exclusive
role in promoting apoptosis (Brodsky et al., 2000; Ollmann et al.,
2000). Accordingly, unlike mammalian cells, D. melanogaster
does not possess some of the pathways needed for recovery after
p53 activation, as judged by the absence of genes encoding for
key negative regulators of p53 (e.g., MDM2). Significantly, our
analysis of the degree of conservation of the different p53 acetylation clusters between mammalian and D. melanogaster p53
(Fig. 9) showed that dp53 possesses a COOH-terminal domain
with homology to the stretch of amino acids containing acetylated residues around position 373 of human p53, as noted by
others (Brodsky et al., 2000), but no detectable K320 homology.
Thus, regulation of p53 activity via K320 acetylation might have
evolved in higher eukaryotes to suppress the apoptotic program
and to allow recovery after damage. We postulate that this reflects
the necessity of complex multicellular organisms to spare the life
of tissues with limited proliferation potential. In strong support
of this interpretation, we have now shown that K320 acetylation
is particularly favored in neuronal cells after injury, where it regulates the expression of genes specifically involved in neuronal
survival and regeneration (unpublished data).
The COOH-terminal tail of p53 and a p53
acetylation code

It is becoming clear that the COOH-terminal region of p53 is a
target of numerous additional posttranslational modifications,
P53
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Figure 9. Conservation of K373 but not K320
between human and D. melanogaster p53.
Human and D. melanogaster p53 were aligned
using LALIGN from GeneStream (http://www.
eng.uiowa.edu/~tscheetz/sequence-analysis/
examples/LALIGN/lalign-guess.html). Identical
residues are shaded in gray, whereas conserved residues are colored in blue. K320 and
K373 are indicated on human p53.

such as phosphorylation, ubiquitination, sumoylation, and methylation (Bode and Dong, 2004). The similarity between the posttranslational modifications that exist in the histone tail and in the
p53 COOH-terminal domain is intriguing. In the case of histones, it has been proposed that different patterns of such modifications, acting alone or in combination on one or more tails,
establish a “histone code” that is deciphered by other proteins to
coordinate downstream events (Strahl and Allis, 2000). In this
model, the recruitment of nucleosome-modifying enzymes and
of effector molecules by such “histone cassettes” will execute
the code by changing local chromatin structure. For p53, the
challenge for further studies will be to understand whether specific combinations of posttranslational modifications do exist
that modify and expand the ability of this protein to regulate
gene expression in a manner similar to that proposed for the histone tail. Experiments presented here suggest that mutations of
each of the two lysine clusters is associated at the very least with
a different phosphorylation pattern in the NH2-terminal region
of p53, with a different ability to interact with coactivators and
corepressors, and with a different gene-expression profile. Moreover, in conditions whereby the activity of each acetylation mutant was studied independently, such as in the H1299 cell lines,
we were able to trace an effect of each acetylation cluster on
apoptosis or on the G1 and G2 checkpoints (Fig. 2). This finding, together with biochemical studies on the phosphorylation
state and interaction profile of p53 acetylation mutants, supports
the idea that the biological activities of p53 may be dictated by
multiple cassettes, each interacting with specific effectors and
containing well-defined combination patterns of posttranslational modifications. This interpretation might explain why so
many posttranslational modifications target p53 (Fig. 8).
Implications for chemotherapy

It is well known that certain organs, such as the central nervous
system, kidney, heart, liver, and lung, are naturally radio
resistant, and there is good evidence that p53 is an important
determinant of tissue-specific radio sensitivity (Gudkov and
Komarova, 2003). We have shown that in a lung tumor cell line,
the extent of K320 or K373 acetylation is qualitatively and
quantitatively influenced by the type and extent of DNA damage.
It is also possible that the extent of acetylation of each of these
sites is determined in a tissue-specific manner by the local availability of acetylases or deacetylases. Based on the fact that
expression of p53Q320 allows for resumption of proliferation
after DNA damage, we predict that strategies aimed at enhancing acetylation of K320 could foster the development of compounds that protect peripheral tissues from toxicity during the
course of chemotherapy.
542

JCB • VOLUME 173 • NUMBER 4 • 2006

Materials and methods
Cell lines, transfections, and the generation of the H1299
tetracycline-inducible cells
H1299 and A549 lung carcinoma cells were grown in DME supplemented
with 10% FCS and 2 mM L-glutamine. The p53 mutants used for the
tetracycline-inducible system were constructed by using a Pfu-polymerase–
based, site-directed mutagenesis (Stratagene), followed by cloning of the
ampliﬁed cDNAs into the pCDNA/TO4 vector (Invitrogen). The primers
used for mutagenesis were as follows: p53Q320, 5′-CCCCAGCCAAAGCAGAAACCACTGGATGGAGAA and p53Q373, 5′-AGCCACCTGCAGTCCCAACAGGGTCAGTCTACC. p53DM was created with two consecutive
rounds of site-directed mutagenesis. A Flag-encoding sequence was fused
in frame to the NH2 terminus of p53 to facilitate immunodetection of
the protein. Transfections were performed by using either Lipofectamine
(Invitrogen) or FuGENE 6 (for coverslips; Roche). Full-length PCAF and
HA-tagged p300 were expressed from pCDNA vectors. Cells were plated
at 20–40% conﬂuence 12–18 h before transfection. Cells were exposed to
the transfection reagent for 16 h, washed twice with PBS, and refed with
complete medium for an additional 24 h. Adozelesin and bizelesin were
provided by T. Beerman (Rowell Park Cancer Institute, Buffalo, NY).
In vivo DNA binding assays
ChIP assays were performed as described elsewhere (Ogawa et al.,
2002). The primers used for ampliﬁcation of p53-responsive elements
were as follows: p21, 5′-TCACCATTCCCCTACCCCATGCTGCTC and
3′-AAGTTTGCAACCATGCACTTGAATGTG; BAX, 5′-AGCTCATGCCTGTAATCCCAGCGCT and 3′-AAATAGCATGCTTCCAGGCAGGACGT;
P53AIP1, 5′-AGCTGAGCTCAAATGCTGAC and 3′-CCAAGTTCTCTGCTTTC; and PIG3, 5′-CAGGACTGTCAGGAGGAGGCGAGTGATAAG and
3′-GTGCGATTCTAGCTCTCACTTCAAGGAGAG.
In vitro puriﬁcation of p53 and EMSAs
p53 was puriﬁed from 10 dishes of SF21 cells infected with recombinant
baculoviruses expressing native or acetylation mutant p53. Cells were harvested and lysed in extraction buffer (20 mM Hepes, pH 7.5, 0.5 M KCl,
0.4 mM EDTA, 0.2% NP-40, 10 mM β-mercaptoethanol, 0.1 mM PMSF,
and 10 μg/ml pepstatin), incubated on ice for 20 min, and centrifuged at
14,000 g for 30 min at 4°C. p53 was puriﬁed by using a anti-Flag immunoafﬁnity column (Sigma-Aldrich) in the presence of 0.5 M KCl, extensively
washed, and eluted with the Flag peptide. EMSAs were performed in a
30 μl total volume that contained buffer A (5× 100 mM Hepes, pH 7.9,
125 mM KCl, 0.5 mM EDTA, 50% glycerol, and 10 mM MgCl2); buffer B
(10× 10 mM spermidine, 40 mM DTT, 1.2% NP-40, and 2 mg/ml BSA);
10 ng of double-stranded poly(d[I-C]); 50 ng of labeled oligonucleotide;
and 50, 75, or 150 ng of p53. Reactions were incubated with the probe at
room temperature for 20–40 min and run on native 6% polyacrylamide gels,
which were run at room temperature until the xylen-cyanol blue reached
6 cm from the bottom of the gel. The oligonucleotides used were as follows:
p21/WAF, 5′-TCTGGCCATCAGGAACATGTCCCAACATGTTGAGCTCTGG and 3′CCAGAGCTCAACATGTTGGGACATGTTCCTGATGGCCAGA;
Gadd45, 5′TCTGTGGTACAGAACATGTCTAAGCATGCTGGGGACTGCC
and 3′-GGCAGTCCCCAGCATGCTTAGACATGTTCTGTACCACAGA; and
Bax, 5′AATTCGGCTACCTCACAAGTTAGAGACAAGCCTGGGCGTGGGCTATATTGTAGCGAAT and 3′-ATTCGCTACAATATAGCCCACGCCCAGGCTTGTCTCTAACTTGTGAGGTAGCCGAATT.
Immunoprecipitations and immunoblots
Preparation of cell extracts and immunoprecipitations were performed as
previously described (Avantaggiati et al., 1997). Antibodies used in this
study were for p53 (FL393 and N-19 [Santa Cruz Biotechnology, Inc.] and
Ab-1 and Ab-6 [Calbiochem]), S15-, S46-, and S392-phospho-p53 (Cell
Signaling Technology), Acetyl-320-, Acetyl-373-, and Acetyl-373/382-p53

(Upstate Biotechnology), PCAF (E8; Santa Cruz Biotechnology, Inc.), p300
(N-15; Santa Cruz Biotechnology, Inc.), p21 (WAF1/Ab-5; Calbiochem),
mSin3 (AK-11; Santa Cruz Biotechnology, Inc.), Sir2 (7342; Abcam), Bax
(anti-Bax/NT; Upstate Biotechnology), and actin (I19; Santa Cruz Biotechnology, Inc.). Proteins were detected by using a chemiluminescence-based
system (Pierce Chemical Co.) according to the manufacturer’s instructions.
Indirect immunoﬂuorescence
The H1299 cells were plated on glass coverslips, ﬁxed in 4% paraformaldehyde, and permeabilized by addition of 0.1% Triton X-100/PBS solution.
Cells were stained using antibodies directed against p53 (FL393), PCAF
(E-8), or p300 (N-15) and then stained for DNA content (DAPI; Invitrogen).
The appropriate ﬂuorescent secondary antibodies were obtained from
Invitrogen. Where indicated, cells were treated with 5 ng/ml leptomycin B
(Sigma-Aldrich) for 24 h. Cells were visualized using a microscope
(Axiovert 200; Carl Zeiss MicroImaging, Inc.) with either a 40× or 60×
objective. Images were acquired using a camera (Axio; Carl Zeiss
MicroImaging, Inc.). Analysis of different Z stacks was performed using the
AxioVision 3.0 software (Carl Zeiss MicroImaging, Inc.).
Microarrays
The cDNA microarrays were performed at the Children’s National Medical
Center. H1299 cells expressing WT p53, p53Q320, or p53Q373 were
harvested for total RNA extraction 24 h after the addition of tetracycline.
7 μg total RNA was used for cDNA and biotinylated cRNA synthesis.
Expression-proﬁling analysis was performed using the HG-U133 human
high-density oligonucleotide microarray (Affymetrix, Inc.). Each GeneChip
was used for a single hybridization with RNA isolated from one cell line
from a single experiment. The total number of samples was six.
Expression proﬁling was performed as described previously and
fulﬁlled all stringent quality-control measures as detailed previously
(Di Giovanni et al., 2005). We used two normalization processes: one for
chip–chip comparisons (scaling factors) and one for gene–gene comparisons (normalization to the mean of the naive signal intensities for each
gene). The scaling factor determinations were done using default algorithms (MAS 5.0; Affymetrix, Inc.) with a target intensity of chip sector ﬂuorescence to 800.
We have recently shown that the use of MAS 5.0 signal intensity
values, together with a present call noise ﬁlter achieves an excellent
signal/noise balance relative to other probe set analysis methods (dChip;
robust multichip average [RMA]; Seo et al., 2004). Data analyses were
limited to probe sets that showed one or more “present” (P “calls”) in the
six GeneChip proﬁles in our complete dataset. Data were analyzed and
visualized using the GeneSpring software (Silicon Genetics). Initial data
analysis also included a fold-change ﬁlter of >2 increase or decrease relative to WT p53 (MAS 5.0). Functional classiﬁcation was performed using
DAVID software (http://apps1.niaid.nih.gov/david/upload.jsp).
For hierarchy and clustering analysis, the arrays were analyzed using the R statistics package (http://www.R-project.org) and the Affymetrix,
Inc. library (Irizarry et al., 2003) of the Bioconductor software package.
Expression values were determined using the RMA algorithm using the
RMA function in the Affymetrix, Inc. library at its default settings. Genes
that exhibited an expression change >2 relative to the control (WT p53)
for at least one of replicates and one of the mutations were selected for further analysis. These genes were then clustered using hierarchical clustering
with “complete” agglomeration, and each cluster was further analyzed
based on the known function of the genes contained in the cluster.
Semiquantitative PCR was performed using random hexamer
priming for ﬁrst-strand synthesis (SuperScript III; Invitrogen), followed by
ampliﬁcation of speciﬁc genes with Taq polymerase and the following
primer pairs: Jagged-2, 5′-GTTGACGCACCTGTGGTTGT-3′ and 5′-CTTCAATACTGCCGCCGTCC-3′ (32 cycles); pig11, 5′-GGCTGACAACTGGCTGTCTT-3′ and 5′-ACAGGCCATGTTGCTGTATC-3′ (35 cycles); APAF-1,
5′-TCTACCTCTGCTGACAAGAC-3′ and 5′-GTAGCAGCTCCTTCTTCTGA-3′
(35 cycles); and actin, 5′-GCTCGTCGTCGACAACGGCT-3′ and 5′-CAAACATGATCTGGGTCATCTTCTC-3′ (26 cycles).
Online supplemental material
Fig. S1 demonstrates that mixed populations of H1299–WT p53,
p53Q320, p53Q373, or p53DM clones display similar cell cycle proﬁles
and viability compared with a single clone population after p53 protein
induction. In Fig. S2, EMSAs are used to study the DNA binding activity of
p53 acetylation mimics in the absence of chromatin. Finally, Fig. S3 demonstrates that the p53 protein puriﬁed from baculovirus-infected incest cells
has a high level of purity. Table S1 depicts apoptotic and cell cycle–related

genes inﬂuenced in H1299 cells by the expression of the p53Q320 and
-Q373 acetyl-mimics. Online supplemental material is available at http://
www.jcb.org/cgi/content/full/jcb.200512059/DC1.
This work was supported by grants from the National Institutes of Health (R01
CA83979, R01 CA030716, and R01 CA102746 to M.L. Avantaggiati,
and R01 CA70896, R01 CA75503, and R01 CA86072 to R.G. Pestell) and
T32 Training Fellowship (CA009686 to C. Knights). Work conducted at the
Lombardi Comprehensive Cancer Center was supported by the Comprehensive Cancer Center Core National Institutes of Health grant CA51008-14.

Submitted: 12 December 2005
Accepted: 18 April 2006

References
Appella, E., and C.W. Anderson. 2001. Post-translational modifications and
activation of p53 by genotoxic stresses. Eur. J. Biochem. 268:2764–2772.
Avantaggiati, M.L., V. Ogryzko, K. Gardner, A. Giordano, A.S. Levine, and K.
Kelly. 1997. Recruitment of p300/CBP in p53-dependent signal pathways.
Cell. 89:1175–1184.
Bates, S., E.S. Hickman, and K.H. Vousden. 1999. Reversal of p53-induced
cell-cycle arrest. Mol. Carcinog. 24:7–14.
Bode, A.M., and Z. Dong. 2004. Post-translational modification of p53 in
tumorigenesis. Nat. Rev. Cancer. 4:793–805.
Brodsky, M.H., W. Nordstrom, G. Tsang, E. Kwan, G.M. Rubin, and J.M.
Abrams. 2000. Drosophila p53 binds a damage response element at the
reaper locus. Cell. 101:103–113.
Derry, W.B., A.P. Putzke, and J.H. Rothman. 2001. Caenorhabditis elegans p53:
role in apoptosis, meiosis, and stress resistance. Science. 294:591–595.
Di Giovanni, S., A. De Biase, A. Yakovlev, T. Finn, J. Beers, E.P. Hoffman, and
A.I. Faden. 2005. In vivo and in vitro characterization of novel neuronal
plasticity factors identified following spinal cord injury. J. Biol. Chem.
280:2084–2091.
Fukuda, M., S. Asano, T. Nakamura, M. Adachi, M. Yoshida, M. Yanagida, and
E. Nishida. 1997. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature. 390:308–311.
Gu, W., and R.G. Roeder. 1997. Activation of p53 sequence-specific DNA
binding by acetylation of the p53 C-terminal domain. Cell. 90:595–606.
Gudkov, A.V., and E.A. Komarova. 2003. The role of p53 in determining
sensitivity to radiotherapy. Nat. Rev. Cancer. 3:117–129.
Irizarry, R.A., B.M. Bolstad, F. Collin, L.M. Cope, B. Hobbs, and T.P. Speed.
2003. Summaries of Affymetrix GeneChip probe level data. Nucleic
Acids Res. 31:e15.
Jones, R.G., D.R. Plas, S. Kubek, M. Buzzai, J. Mu, Y. Xu, M.J. Birnbaum, and
C.B. Thompson. 2005. AMP-activated protein kinase induces a p53dependent metabolic checkpoint. Mol. Cell. 18:283–293.
Kim, Y.Y., B.J. Park, D.J. Kim, W.H. Kim, S. Kim, K.S. Oh, J.Y. Lim, J. Kim, C.
Park, and S.I. Park. 2004. Modification of serine 392 is a critical event in
the regulation of p53 nuclear export and stability. FEBS Lett. 572:92–98.
Knights, C.D., Y. Liu, E. Appella, and M. Kulesz-Martin. 2003. Defective p53
post-translational modification required for wild type p53 inactivation in
malignant epithelial cells with mdm2 gene amplification. J. Biol. Chem.
278:52890–52900.
Lee, C.S., G.P. Pfeifer, and N.W. Gibson. 1994. Mapping of DNA alkylation sites
induced by adozelesin and bizelesin in human cells by ligation-mediated
polymerase chain reaction. Biochemistry. 33:6024–6030.
Liang, S.H., and M.F. Clarke. 2001. Regulation of p53 localization. Eur. J.
Biochem. 268:2779–2783.
Lill, N.L., S.R. Grossman, D. Ginsberg, J. DeCaprio, and D.M. Livingston.
1997. Binding and modulation of p53 by p300/CBP coactivators. Nature.
387:823–827.
Liu, L., D. Scolnick, R. Trievel, H. Zhang, R. Marmorstein, T.D. Halazonetis,
and S. Berger. 1999. p53 sites acetylated in vitro by PCAF and p300
are acetylated in vivo in response to DNA damage. Mol. Cell. Biol.
19:1202–1209.
Luo, J., M. Li, Y. Tang, M. Laszkowska, R.G. Roeder, and W. Gu. 2004.
Acetylation of p53 augments its site-specific DNA binding both in vitro
and in vivo. Proc. Natl. Acad. Sci. USA. 101:2259–2264.
McLure, K.G., and P.W. Lee. 1996. A PAb240+ conformation of wild type p53
binds DNA. Oncogene. 13:1297–1303.
Murphy, M., J. Ahn, K.K. Walker, W.H. Hoffman, R.M. Evans, A.J. Levine, and
D.L. George. 1999. Transcriptional repression by wild-type p53 utilizes
histone deacetylases, mediated by interaction with mSin3a. Genes Dev.
13:2490–2501.

P53

ACETYLATION: SURVIVAL OR DEATH • KNIGHTS ET AL.

543

Oda, K., H. Arakawa, T. Tanaka, K. Matsuda, C. Tanikawa, T. Mori, H. Nishimori,
K. Tamai, T. Tokino, Y. Nakamura, and Y. Taya. 2000. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46phosphorylated p53. Cell. 102:849–862.
Ogawa, H., K. Ishiguro, S. Gaubatz, D.M. Livingston, and Y. Nakatani. 2002.
A complex with chromatin modifiers that occupies E2F- and Mycresponsive genes in G0 cells. Science. 296:1132–1136.
Ollmann, M., L.M. Young, C.J. Di Como, F. Karim, M. Belvin, S. Robertson, K.
Whittaker, M. Demsky, W.W. Fisher, A. Buchman, et al. 2000. Drosophila
p53 is a structural and functional homolog of the tumor suppressor p53.
Cell. 101:91–101.
Prives, C., and J.L. Manley. 2001. Why is p53 acetylated? Cell. 107:815–818.
Resnick, M.A., and A. Inga. 2003. Functional mutants of the sequence-specific
transcription factor p53 and implications for master genes of diversity.
Proc. Natl. Acad. Sci. USA. 100:9934–9939.
Sakaguchi, K., J. Herrera, S. Saito, T. Miki, M. Bustin, A. Vassilev, C.W.
Anderson, and E. Appella. 1998. DNA damage activates p53 through a
phosphorylation-acetylation cascade. Genes Dev. 12:2831–2841.
Seo, J., M. Bakay, Y.W. Chen, S. Hilmer, B. Shneiderman, and E.P. Hoffman.
2004. Interactively optimizing signal-to-noise ratios in expression profiling: project-specific algorithm selection and detection p-value weighting
in Affymetrix microarrays. Bioinformatics. 20:2534–2544.
Strahl, B.D., and C.D. Allis. 2000. The language of covalent histone modifications.
Nature. 403:41–45.
Tomso, D.J., A. Inga, D. Menendez, G.S. Pittman, M.R. Campbell, F. Storici,
D.A. Bell, and M.A. Resnick. 2005. Functionally distinct polymorphic
sequences in the human genome that are targets for p53 transactivation.
Proc. Natl. Acad. Sci. USA. 102:6431–6436.
Unger, T., T. Juven-Gershon, E. Moallem, M. Berger, R. Vogt Sionov, G. Lozano,
M. Oren, and Y. Haupt. 1999. Critical role for Ser20 of human p53 in the
negative regulation of p53 by Mdm2. EMBO J. 18:1805–1814.
Vousden, K.H., and C. Prives. 2005. P53 and prognosis; new insights and further
complexity. Cell. 120:7–10.
Zhang, Y., and Y. Xiong. 2001. A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science.
292:1910–1915.

544

JCB • VOLUME 173 • NUMBER 4 • 2006

